Immunogenicity and safety of a single dose of adjuvanted RSVPreF3 vaccine in adults ≥60 years of age in China: results from a phase 3 immunobridging trial
IntroductionRespiratory syncytial virus (RSV) is an important cause of severe respiratory disease, yet no vaccine is available for older adults in China. This phase 3, randomized, partially blind immunobridging study (NCT06551181) compared a single dos…